MA30088B1 - Phenethylamines substituees possedant une activite serotoninergique et/ou norepinephrinergique - Google Patents
Phenethylamines substituees possedant une activite serotoninergique et/ou norepinephrinergiqueInfo
- Publication number
- MA30088B1 MA30088B1 MA31078A MA31078A MA30088B1 MA 30088 B1 MA30088 B1 MA 30088B1 MA 31078 A MA31078 A MA 31078A MA 31078 A MA31078 A MA 31078A MA 30088 B1 MA30088 B1 MA 30088B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorder
- treatment
- neurotransmitters
- anxiety disorder
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
PHÉNÉTHYLAMINES SUBSTITUÉES POSSÉDANT UNE ACTIVITÉ SÉROTONINERGIQUE ET/OU NORÉPINÉPHRINERGIQUE La présente invention a pour objet des synthèses chimiques et des applications médicales de nouveaux inhibiteurs de capture de neurotransmetteurs de type monoamine et de sels et promédicaments de qualité pharmaceutique desdits inhibiteurs, dans le traitement et/ou le contrôle d'un trouble psychotrope, d'un trouble de l'anxiété, d'un trouble de l'anxiété généralisée, de la dépression, d'un trouble de stress post-traumatique, d'un trouble obsessionnel compulsif, d'un trouble de panique, de bouffées de chaleur, de la démence sénile, de la migraine, du syndrome hépatopulmonaire, de la douleur chronique, de la douleur nociceptive, de la douleur névropathique, de la rétinopathie diabétique douloureuse, de la dépression bipolaire, de l'apnée obstructive, des troubles psychiatriques, du trouble dysphorique prémenstruel, de la phobie sociale, du trouble d'anxiété sociale, de l'incontinence urinaire, de l'anorexie, de la boulimie nerveuse, de l'obésité, de l'ischémie, des blessures à la tête, de la surcharge de calcium dans les cellules du cerveau, de la dépendance aux drogues et/ou de l'éjaculation précoce.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74131505P | 2005-12-01 | 2005-12-01 | |
US84136606P | 2006-08-30 | 2006-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30088B1 true MA30088B1 (fr) | 2008-12-01 |
Family
ID=37776574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31078A MA30088B1 (fr) | 2005-12-01 | 2008-06-26 | Phenethylamines substituees possedant une activite serotoninergique et/ou norepinephrinergique |
Country Status (19)
Country | Link |
---|---|
US (9) | US7456317B2 (fr) |
EP (2) | EP1954669B1 (fr) |
JP (1) | JP5302005B2 (fr) |
KR (1) | KR101068180B1 (fr) |
AU (1) | AU2006320655A1 (fr) |
BR (1) | BRPI0620587A2 (fr) |
CA (1) | CA2631581C (fr) |
DK (1) | DK1954669T3 (fr) |
EA (1) | EA200801488A1 (fr) |
ES (1) | ES2549079T3 (fr) |
HK (1) | HK1125626A1 (fr) |
HU (1) | HUE027865T2 (fr) |
IL (1) | IL191847A0 (fr) |
MA (1) | MA30088B1 (fr) |
NZ (1) | NZ568720A (fr) |
PL (1) | PL1954669T3 (fr) |
PT (1) | PT1954669E (fr) |
SI (1) | SI1954669T1 (fr) |
WO (1) | WO2007064697A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100076087A1 (en) * | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
EP1954669B1 (fr) | 2005-12-01 | 2015-07-08 | Auspex Pharmaceuticals, Inc. | Phénétylamines substituées à l activité sérotoninergique et/ou norépinephrinergique |
EP2075310B1 (fr) * | 2006-08-31 | 2012-03-14 | Nippon Steel Chemical Co., Ltd. | Matériau de dispositif électroluminescent organique et dispositif électroluminescent organique |
EP2514740B1 (fr) | 2007-03-15 | 2018-12-19 | Auspex Pharmaceuticals, Inc. | O-desmethylvenlafaxines deuteres a action sérotoninergique et/ou norepinephrinergique |
US7767860B2 (en) | 2007-09-06 | 2010-08-03 | Auspex Pharmaceuticals, Inc | Substituted amino alcohols |
US20110053968A1 (en) * | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
US8586760B2 (en) * | 2009-06-15 | 2013-11-19 | Auspex Pharmaceuticals, Inc. | Aminothiazole modulators of beta-3-adrenoreceptor |
AU2010300531A1 (en) | 2009-09-30 | 2012-05-24 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
US8575174B2 (en) | 2011-06-20 | 2013-11-05 | H. Lundbeck A/S | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia |
EA201691582A1 (ru) | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
CN104059030B (zh) | 2014-05-30 | 2016-05-04 | 镇江圣安医药有限公司 | [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途 |
WO2017079102A1 (fr) | 2015-11-03 | 2017-05-11 | Albert Einstein College Of Medicine, Inc. | Utilisation de réactifs de dérivation 13c pour l'identification et la quantification de produits chimiques par couplage chromatographie gazeuse ou liquide-spectrométrie de masse |
US11535600B2 (en) | 2018-12-03 | 2022-12-27 | H. Lundbeck A/S | Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine |
MX2022014605A (es) | 2020-05-19 | 2022-12-16 | Cybin Irl Ltd | Derivados de triptamina deuterada y metodos de uso. |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069346A (en) | 1977-02-14 | 1978-01-17 | The Dow Chemical Company | Compositions and methods for anesthetizing an animal using deuterated analogues of halothane and chloroform |
IE56324B1 (en) * | 1982-12-13 | 1991-06-19 | American Home Prod | Phenethylamine derivatives and intermediates therefor |
US4535186A (en) | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
SE9002043D0 (sv) | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
US6440457B1 (en) | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
ATE392893T1 (de) | 1993-06-28 | 2008-05-15 | Wyeth Corp | Neue behandlungsmethoden durch verwendung von phenethylaminderivaten |
TW344661B (en) | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
WO1995026325A2 (fr) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Potentialisation de medicaments par deuteration_______________ |
US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
US20030215507A1 (en) * | 1996-03-25 | 2003-11-20 | Wyeth | Extended release formulation |
US6884429B2 (en) | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
JP4261049B2 (ja) | 1997-10-08 | 2009-04-30 | アイソテクニカ インコーポレイテッド | 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用 |
US6579899B1 (en) | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
US6333342B1 (en) | 1998-11-04 | 2001-12-25 | Isotechnika, Inc | Methods of pharmacological treatment using S(−) amlodipine |
US6197828B1 (en) * | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
US6071918A (en) * | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
AR025110A1 (es) | 1999-08-13 | 2002-11-06 | Vela Pharmaceuticals Inc | Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina |
US20050233459A1 (en) * | 2003-11-26 | 2005-10-20 | Melker Richard J | Marker detection method and apparatus to monitor drug compliance |
DK1104760T3 (da) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
EP1134290A3 (fr) * | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Modèles pharmacophores pour l'identification de l'efficacité inhibitoire à CYP2D6 des inhibiteurs sélectifs de récaptage de sérotonine |
US20020183553A1 (en) * | 2000-10-19 | 2002-12-05 | Ben-Zion Dolitzky | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
US20050054942A1 (en) | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
EP1864967A1 (fr) | 2001-02-12 | 2007-12-12 | Wyeth | Procédé de fabrication d'O-desméthyl-venlafaxine |
AU2002303427A1 (en) | 2001-04-24 | 2002-11-05 | East Carolina University | Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease |
IL146462A (en) | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
US20070015786A1 (en) | 2003-12-12 | 2007-01-18 | Eli Lily And Company | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition |
US20050181071A1 (en) | 2004-02-18 | 2005-08-18 | Binder Michael R. | Method for the treatment of clinical depression |
EP1735296B1 (fr) * | 2004-04-08 | 2009-12-09 | Aryx Therapeutics | Materiaux et procedes de traitement de troubles de la coagulation |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
CN101065014A (zh) | 2004-09-23 | 2007-10-31 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质系统的方法 |
EP1812010A2 (fr) | 2004-10-18 | 2007-08-01 | BTG International Limited | Utilisation d'inhibiteurs de la na+/k+-atpase et leurs antagonistes |
US20080033011A1 (en) | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
US20100076087A1 (en) | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
EP1948248A2 (fr) | 2005-11-06 | 2008-07-30 | Katz-Brull, Rachel | Imagerie par resonance magnetique et moyen de spectroscopie et procedes associes |
EP1954669B1 (fr) | 2005-12-01 | 2015-07-08 | Auspex Pharmaceuticals, Inc. | Phénétylamines substituées à l activité sérotoninergique et/ou norépinephrinergique |
US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
US20090312435A1 (en) * | 2006-08-30 | 2009-12-17 | Auspex Pharmaceuticals, Inc | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
EP2514740B1 (fr) | 2007-03-15 | 2018-12-19 | Auspex Pharmaceuticals, Inc. | O-desmethylvenlafaxines deuteres a action sérotoninergique et/ou norepinephrinergique |
WO2008141033A1 (fr) * | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals Inc. | Naphtalènes substitués |
US20090028873A1 (en) | 2007-07-27 | 2009-01-29 | Auspex Pharmaceuticals, Inc. | Substituted cyclohexanols |
US20090069431A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched milnacipran |
US20090076162A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched desvenlafaxine |
US20100007087A1 (en) * | 2008-07-09 | 2010-01-14 | John Michael Pryke | Six fold game board and method of folding game board |
WO2010028130A2 (fr) | 2008-09-03 | 2010-03-11 | Concert Pharmaceuticals, Inc. | Composés antidépresseurs |
-
2006
- 2006-11-30 EP EP06844628.5A patent/EP1954669B1/fr active Active
- 2006-11-30 BR BRPI0620587-9A patent/BRPI0620587A2/pt not_active IP Right Cessation
- 2006-11-30 DK DK06844628.5T patent/DK1954669T3/en active
- 2006-11-30 CA CA2631581A patent/CA2631581C/fr active Active
- 2006-11-30 WO PCT/US2006/045673 patent/WO2007064697A1/fr active Application Filing
- 2006-11-30 PT PT68446285T patent/PT1954669E/pt unknown
- 2006-11-30 KR KR1020087015962A patent/KR101068180B1/ko active IP Right Grant
- 2006-11-30 SI SI200631981T patent/SI1954669T1/sl unknown
- 2006-11-30 PL PL06844628T patent/PL1954669T3/pl unknown
- 2006-11-30 EA EA200801488A patent/EA200801488A1/ru unknown
- 2006-11-30 AU AU2006320655A patent/AU2006320655A1/en not_active Abandoned
- 2006-11-30 US US11/565,451 patent/US7456317B2/en active Active
- 2006-11-30 JP JP2008543418A patent/JP5302005B2/ja not_active Expired - Fee Related
- 2006-11-30 NZ NZ568720A patent/NZ568720A/en not_active IP Right Cessation
- 2006-11-30 ES ES06844628.5T patent/ES2549079T3/es active Active
- 2006-11-30 HU HUE06844628A patent/HUE027865T2/en unknown
- 2006-11-30 EP EP15175770.5A patent/EP2998288B1/fr active Active
-
2008
- 2008-05-29 IL IL191847A patent/IL191847A0/en unknown
- 2008-06-26 MA MA31078A patent/MA30088B1/fr unknown
- 2008-09-19 US US12/234,318 patent/US8138226B2/en active Active
- 2008-09-19 US US12/234,236 patent/US9422225B2/en active Active
-
2009
- 2009-05-13 HK HK09104374.9A patent/HK1125626A1/xx not_active IP Right Cessation
-
2014
- 2014-06-17 US US14/306,396 patent/US9458082B2/en active Active
-
2016
- 2016-07-08 US US15/205,491 patent/US20160318847A1/en not_active Abandoned
- 2016-08-23 US US15/244,575 patent/US20160361275A1/en not_active Abandoned
-
2017
- 2017-05-17 US US15/597,516 patent/US20180085327A1/en not_active Abandoned
-
2018
- 2018-05-09 US US15/975,570 patent/US20180256517A1/en not_active Abandoned
-
2019
- 2019-03-04 US US16/291,126 patent/US20200060995A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30088B1 (fr) | Phenethylamines substituees possedant une activite serotoninergique et/ou norepinephrinergique | |
WO2009003868A3 (fr) | 2-imidazolines | |
CY1118174T1 (el) | ΔΕΥΤΕΡΙΩΜΕΝΗ d9-ΒΕΝΛΑΦΑΞΙΝΗ | |
UA98951C2 (ru) | 2-аминооксазолины и лекарственное средство, которое их содержит | |
TW200833685A (en) | Aminomethyl-4-imidazoles | |
NO20091480L (no) | Aminometyl-2-imidazoler med affinitet mot sporamin-assosierte reseptorer | |
WO2007058998A3 (fr) | Phenylpiperidines substituees a activite serotoninergique et proprietes therapeutiques ameliorees | |
AR059206A1 (es) | Uso de derivados de 4-imidazol para trastornos del snc | |
NO20065814L (no) | Thiendopyridinon forbindelser og fremgangsmater for behandling | |
HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
RU2008108219A (ru) | Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств | |
NZ617334A (en) | Cyclopropyl amine derivatives | |
NO20083349L (no) | Anvendelse av 2-imidazoler for behandling av CNS sykdommer | |
NZ597498A (en) | Cyclopropyl amine derivatives as histamin H3 receptor modulators | |
MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
MX2009006215A (es) | 4-imidazolinas como ligandos de aminas trazas. | |
MX2009013745A (es) | 4-imidazolinas y su uso como antidepresivos. | |
MX2009004617A (es) | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. | |
WO2007090720A3 (fr) | Utilisation de 2-imidazoles pour le traitement de troubles du système nerveux central | |
NZ597219A (en) | Novel fumarate salts of a histamine h3 receptor antagonist | |
MX2009005047A (es) | 4-imidazoles sustituidos. | |
RU2010120847A (ru) | Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
MX2010009403A (es) | Derivados de 2-aminoquinolina. |